Abstract
The risk of vertical transmission of hepatitis C virus (HCV) is ≈6%, and there is growing evidence that maternal HCV adversely affects pregnancy and infant outcomes. However, antenatal HCV screening is not routinely provided in most settings, and direct acting antivirals (DAA) are not approved for pregnant/ breastfeeding women. We conducted a cross-sectional survey of pregnant/post-partum women in Egypt, Pakistan and Ukraine to assess the acceptability of universal antenatal HCV screening and DAA treatment in the scenario of DAAs being approved for use in pregnancy. Among 630 women (n=210 per country), 73% were pregnant and 27% postpartum, 27% ever HCV antibody or PCR positive. Overall, 93% of women supported HCV screening and 88% would take DAAs in pregnancy (92%, 98% and 73% in Egypt, Pakistan and Ukraine, respectively), mostly to prevent vertical transmission/adverse pregnancy outcomes. Clinical trials to evaluate the safety and efficacy of DAAs in pregnancy are urgently needed.
Competing Interest Statement
MHE-S received an educational grant to attend EASL 2019 (Gilead Sciences) and minor honorarium for participating in a podcast on career development and achievements in viral hepatitis (Gilead Sciences).
Funding Statement
This survey was conducted as part of the HCVAVERT study, funded by the UK Medical Research Council (ref MR/R019746/1).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
UCL Research Ethics Committee
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Abbreviations
- HCV
- Hepatitis C virus
- DAAs
- Direct acting antivirals
- PCR
- Polymerase chain reaction
- WHO
- World Health Organization
- RNA
- Ribonucleic acid
- LMIC
- Low and middle-income countries
- HIV
- Human immunodeficiency virus
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, University of Washington, and Vrije Universiteit Amsterdam.
Subject Area
Reviews and Context
0
Comment
0
TRIP Peer Reviews
0
Community Reviews
0
Automated Services
0
Blogs/Media
Author Videos